Signatera™ for Liver Cancer

Signatera™ is setting the standard for MRD testing in hepatocellular carcinoma. Each assay is custom-designed to detect molecular residual disease earlier than standard-of-care tools, giving you actionable insight to guide post-surgical and post-transplant risk stratification and surveillance decisions.

Order Signatera™ test

Inform clinical challenges in liver cancer

Identify high risk patients

50%

of resected HCC patients relapse within 2 years.

Risk stratify

100%

of Signatera™-positive patients in the MRD window went on to recur.¹

Catch recurrence sooner

7.9

months was the median lead time Signatera™ detected recurrence ahead of imaging, compared to 2.2 months for AFP (P<0.04).¹

SGN_WB_GR_Prov_Liver_HCC_20260121_NAT-8023455_TextImage

Risk stratify based on Signatera™ status at the MRD window

The real world study analyzes 125 HCC patients across four clinical scenarios to assess the utility of Signatera™ after liver transplantation, surgery, or during systemic therapy:

Signatera™ demonstrated strong prognostic utility All patients with Signatera™ positivity after resection relapsed (MRD: HR 7.2, P < 0.0001, Surveillance: HR = 18.0, P < 0.0001).10

Reade the publication

Catch recurrence sooner while intervention is still possible

Signatera™ detected recurrence earlier than imaging or AFP In post-surgical patients, Signatera™ detected relapse 7.9 months earlier than clinical recurrence, outperforming AFP (median lead time 2.2 months).¹

Signatera™ ctDNA dynamics correlated with clinical benefit and utility

Changes in Signatera levels during treatment correlated with clinical outcomes: All patients with decreasing ctDNA experienced clinical benefit* while those with rising ctDNA had progression or relapse.¹

Clinical questions Signatera™ may help answer in liver cancer

Is Signatera™ for Liver cancer right for your patients?

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Abdelrahim, et al. The Feasibility of Personalized and Tumor-Informed ctDNA Assay for Early Recurrence Detection in Patients with Hepatocellular Carcinoma. JCO precision oncology, 2025